GlassScriptPhysician profile
Leonard J Pianko
NPI 1063445351
$7,484.59
in general payments reported to CMS, 2019-2025
51 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $646 · 2021: $893 · 2022: $805 · 2023: $1,172 · 2024: $1,116 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,249.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $879.57 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $771.19 | 2019-2025 | |
| Heartflow, INC. | $660.95 | 2022-2025 | Ffrct |
| Pfizer INC. | $590.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $557.21 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $384.28 | 2019-2024 | Eliquis, Camzyos |
| Boston Scientific Corporation | $342.84 | 2021-2025 | Watchman Flx, Watchman Access System |
| Amarin Pharma, INC. | $301.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.00 | 2019-2024 | Jardiance |
| Medtronic, INC. | $216.18 | 2021-2024 | Pulseselect |
| Abbott Laboratories | $198.55 | 2019-2023 | Aveir |
| Lilly USA, LLC | $182.05 | 2020-2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $154.98 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $154.05 | 2023-2025 | |
| Madrigal Pharmaceuticals | $134.77 | 2025 | Rezdiffra |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $134.55 | 2024-2025 | Opsumit, Uptravi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.84 | 2019-2024 | Xifaxan, Trulance |
| Abiomed | $128.80 | 2024-2025 | Impella |
| Esperion Therapeutics, INC. | $122.62 | 2020-2025 | Nexletol |
| Cvrx, INC. | $90.29 | 2021-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $88.40 | 2019-2025 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.69 | 2025 | Caplyta |
| Lundbeck LLC | $71.55 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $69.56 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $65.16 | 2022-2025 | Verquvo |
| Amgen INC. | $64.44 | 2021-2025 | Repatha, Repatha |
| Abbvie INC. | $53.56 | 2020-2023 | |
| Astellas Pharma US INC | $46.61 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $46.53 | 2023 | Edarbi |
| Sunovion Pharmaceuticals INC. | $45.86 | 2019-2022 | |
| Cipher Pharmaceuticals US LLC | $41.68 | 2025 | Spinosad, Natroba |
| Ibsa Pharma INC. | $41.31 | 2022 | |
| Mylan Specialty L.P. | $41.13 | 2019 | |
| Urovant Sciences INC | $35.73 | 2022 | |
| Philips North America LLC | $32.19 | 2025 | Extended Holter |
| Kestra Medical Technology Services, INC. | $31.00 | 2025 | Assure Wcd |
| Baxter Healthcare | $23.60 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $23.50 | 2023 | Arcalyst |
| Viatris Specialty LLC | $23.19 | 2025 | Yupelri |
| United Therapeutics Corporation | $22.96 | 2025 | Tyvaso |
| Idorsia Pharmaceuticals US INC | $22.40 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $22.00 | 2023 | |
| Dexcom, INC. | $20.49 | 2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $19.74 | 2025 | |
| Exact Sciences Corporation | $18.31 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $18.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2023 | Austedo Xr |
| Arbor Pharmaceuticals, INC. | $14.70 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.88 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Pianko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.